Lack of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Large Cohort of Previously Infected Persons. (5th November 2020)
- Record Type:
- Journal Article
- Title:
- Lack of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Large Cohort of Previously Infected Persons. (5th November 2020)
- Main Title:
- Lack of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Large Cohort of Previously Infected Persons
- Authors:
- Petersen, Lyle R
Sami, Samira
Vuong, Nga
Pathela, Preeti
Weiss, Don
Morgenthau, Beth Maldin
Henseler, Rebecca A
Daskalakis, Demetre C
Atas, Jenny
Patel, Anita
Lukacs, Susan
Mackey, Lisa
Grohskopf, Lisa A
Thornburg, Natalie
Akinbami, Lara J - Abstract:
- Abstract: Background: Reports suggest that some persons previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lack detectable immunoglobulin G (IgG) antibodies. We aimed to determine the proportion IgG seronegative and predictors for seronegativity among persons previously infected with SARS-CoV-2. Methods: We analyzed serologic data collected from healthcare workers and first responders in New York City and the Detroit metropolitan area with a history of a positive SARS-CoV-2 reverse-transcription polymerase chain reaction (RT-PCR) test result and who were tested for IgG antibodies to SARS-CoV-2 spike protein at least 2 weeks after symptom onset. Results: Of 2547 persons with previously confirmed SARS-CoV-2 infection, 160 (6.3%) were seronegative. Of 2112 previously symptomatic persons, the proportion seronegative slightly increased from 14 to 90 days post symptom onset ( P = .06). The proportion seronegative ranged from 0% among 79 persons previously hospitalized to 11.0% among 308 persons with asymptomatic infections. In a multivariable model, persons who took immunosuppressive medications were more likely to be seronegative (31.9%; 95% confidence interval [CI], 10.7%–64.7%), while participants of non-Hispanic Black race/ethnicity (vs non-Hispanic White; 2.7%; 95% CI, 1.5%–4.8%), with severe obesity (vs under/normal weight; 3.9%; 95% CI, 1.7%–8.6%), or with more symptoms were less likely to be seronegative. Conclusions: In our populationAbstract: Background: Reports suggest that some persons previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lack detectable immunoglobulin G (IgG) antibodies. We aimed to determine the proportion IgG seronegative and predictors for seronegativity among persons previously infected with SARS-CoV-2. Methods: We analyzed serologic data collected from healthcare workers and first responders in New York City and the Detroit metropolitan area with a history of a positive SARS-CoV-2 reverse-transcription polymerase chain reaction (RT-PCR) test result and who were tested for IgG antibodies to SARS-CoV-2 spike protein at least 2 weeks after symptom onset. Results: Of 2547 persons with previously confirmed SARS-CoV-2 infection, 160 (6.3%) were seronegative. Of 2112 previously symptomatic persons, the proportion seronegative slightly increased from 14 to 90 days post symptom onset ( P = .06). The proportion seronegative ranged from 0% among 79 persons previously hospitalized to 11.0% among 308 persons with asymptomatic infections. In a multivariable model, persons who took immunosuppressive medications were more likely to be seronegative (31.9%; 95% confidence interval [CI], 10.7%–64.7%), while participants of non-Hispanic Black race/ethnicity (vs non-Hispanic White; 2.7%; 95% CI, 1.5%–4.8%), with severe obesity (vs under/normal weight; 3.9%; 95% CI, 1.7%–8.6%), or with more symptoms were less likely to be seronegative. Conclusions: In our population with previous RT-PCR–confirmed infection, approximately 1 in 16 persons lacked IgG antibodies. Absence of antibodies varied independently by illness severity, race/ethnicity, obesity, and immunosuppressive drug therapy. The proportion seronegative remained relatively stable among persons tested up to 90 days post symptom onset. Abstract : Our data suggest that a sizable proportion of persons do not have immunoglobulin G antibodies following severe acute respiratory syndrome coronavirus 2 infection, which independently relates to illness severity, race/ethnicity, obesity, and immunosuppressive medication. These factors should be considered when interpreting results of serologic testing. … (more)
- Is Part Of:
- Clinical infectious diseases. Volume 73:Number 9(2021)
- Journal:
- Clinical infectious diseases
- Issue:
- Volume 73:Number 9(2021)
- Issue Display:
- Volume 73, Issue 9 (2021)
- Year:
- 2021
- Volume:
- 73
- Issue:
- 9
- Issue Sort Value:
- 2021-0073-0009-0000
- Page Start:
- e3066
- Page End:
- e3073
- Publication Date:
- 2020-11-05
- Subjects:
- SARS-CoV-2 -- antibody -- immunology -- risk factors
Communicable diseases -- Periodicals
616.905 - Journal URLs:
- http://cid.oxfordjournals.org ↗
http://ukcatalogue.oup.com/ ↗
http://www.journals.uchicago.edu/CID/journal ↗
http://www.jstor.org/journals/10584838.html ↗ - DOI:
- 10.1093/cid/ciaa1685 ↗
- Languages:
- English
- ISSNs:
- 1058-4838
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.293860
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24962.xml